Loading...

James Yang, MD

Title(s)CLINICAL FELLOW, Dean's Office
SchoolSchool of Medicine
Address155 N Fresno St
Fresno CA 93701
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020 May 29; JCO2000793. Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csoszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüs M, Kato T, Kalemkerian GP, Luo Y, Ebiana V, Pietanza MC, Kim HR. PMID: 32468956.
      View in: PubMed   Mentions:    Fields:    
    2. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 May 29. Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. PMID: 32469185.
      View in: PubMed   Mentions:    Fields:    
    3. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med. 2020 May 29. Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen YM, Chian CF, Liu X, Tan DSW, Bruns R, Straub J, Johne A, Scheele J, Park K, Yang JC. PMID: 32479794.
      View in: PubMed   Mentions: 3     Fields:    
    4. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. Oncologist. 2020 May 09. Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Liu YN, Su KY, Chang YL, Wu CT, Liao BC, Hsu CC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. PMID: 32386255.
      View in: PubMed   Mentions:    Fields:    
    5. The Inhibition of Wnt Restrain KRASG12V-Driven Metastasis in Non-Small-Cell Lung Cancer. Cancers (Basel). 2020 Mar 31; 12(4). Hung PS, Huang MH, Kuo YY, Yang JC. PMID: 32244355.
      View in: PubMed   Mentions:
    6. Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer. Clin Transl Radiat Oncol. 2020 May; 22:76-82. Yang WC, Hsu FM, Chen YH, Shih JY, Yu CJ, Lin ZZ, Lu SH, Yang JC, Cheng AL, Kuo SH. PMID: 32280792.
      View in: PubMed   Mentions:
    7. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020 03; 21(3):373-386. Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, Orlov S, Cantarini M, Verheijen RB, Mellemgaard A, Ottesen L, Frewer P, Ou X, Oxnard G. PMID: 32027846.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    8. Precision Management of Advanced Non-Small Cell Lung Cancer. Annu Rev Med. 2020 01 27; 71:117-136. Yang CY, Yang JC, Yang PC. PMID: 31986082.
      View in: PubMed   Mentions: 1     Fields:    
    9. Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet Respir Med. 2020 Jun; 8(6):561-572. Tan DS, Leighl NB, Riely GJ, Yang JC, Sequist LV, Wolf J, Seto T, Felip E, Aix SP, Jonnaert M, Pan C, Tan EY, Ko J, Moody SE, Kim DW. PMID: 31954624.
      View in: PubMed   Mentions: 1     Fields:    
    10. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J Thorac Oncol. 2020 May; 15(5):803-815. Yang JC, Schuler M, Popat S, Miura S, Heeke S, Park K, Märten A, Kim ES. PMID: 31931137.
      View in: PubMed   Mentions: 4     Fields:    
    11. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. J Clin Oncol. 2020 Feb 20; 38(6):538-547. Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ. PMID: 31809241.
      View in: PubMed   Mentions: 2     Fields:    
    12. Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. Ther Adv Med Oncol. 2019; 11:1758835919890286. Liao BC, Griesing S, Yang JC. PMID: 31803256.
      View in: PubMed   Mentions:
    13. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. Eur J Cancer. 2020 01; 124:110-122. Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Su KY, Chang YL, Wu CT, Hsu CC, Liao BC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. PMID: 31760310.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. J Thorac Oncol. 2020 Mar; 15(3):324-343. Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Ahn YC, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F. PMID: 31733357.
      View in: PubMed   Mentions:    Fields:    
    15. Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies. Lung Cancer (Auckl). 2019; 10:125-130. Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JC, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SI. PMID: 32009824.
      View in: PubMed   Mentions:
    16. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2020 01; 139:22-27. Ou SI, Gadgeel SM, Barlesi F, Yang JC, De Petris L, Kim DW, Govindan R, Dingemans AM, Crino L, Léna H, Popat S, Ahn JS, Dansin E, Mitry E, Müller B, Bordogna W, Balas B, Morcos PN, Shaw AT. PMID: 31706099.
      View in: PubMed   Mentions:    Fields:    
    17. A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis. J Thorac Oncol. 2020 01; 15(1):91-100. Yang JC, Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Hozak RR, Nguyen TS, Zhang WL, Enatsu S, Puri T, Orlando M. PMID: 31605797.
      View in: PubMed   Mentions:    Fields:    
    18. The impact of smoking on the effectiveness of immune checkpoint inhibitors - a systematic review and meta-analysis. Acta Oncol. 2020 Jan; 59(1):96-100. Lee KWC, Lord SJ, Kasherman L, Marschner I, Stockler M, Gralla R, Yang JC, Mok T, Lee CK. PMID: 31552770.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2020 01; 15(1):50-61. Hsu CC, Liao BC, Liao WY, Markovets A, Stetson D, Thress K, Yang JC. PMID: 31557536.
      View in: PubMed   Mentions: 1     Fields:    
    20. T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study. J Clin Oncol. 2019 10 20; 37(30):2759-2768. Doran SL, Stevanovic S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, Faquin WC, Hewitt SM, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS. PMID: 31408414.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    21. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncol. 2019 Sep; 15(25):2905-2914. Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Märten A, Cufer T. PMID: 31370698.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    22. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer Res Treat. 2020 Jan; 52(1):284-291. Ahn MJ, Han JY, Kim DW, Cho BC, Kang JH, Kim SW, Yang JC, Mitsudomi T, Lee JS. PMID: 31345012.
      View in: PubMed   Mentions:    Fields:    
    23. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. Eur J Cancer. 2019 08; 117:107-115. Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, Lin ZZ, Lin CC, Yang JC, Yu CJ. PMID: 31279301.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    24. Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. Future Oncol. 2019 Jul; 15(20):2371-2383. Woodford R, Loh Y, Lee J, Cooper W, Marschner I, Lewis CR, Millward M, Lord S, Gralla RJ, Yang JC, Mok T, Lee CK. PMID: 31354046.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. Oncologist. 2019 12; 24(12):e1417-e1425. Lee JH, Chen HY, Hsu FM, Chen JS, Liao WY, Shih JY, Yu CJ, Chen KY, Tsai TH, Yang JC. PMID: 31127020.
      View in: PubMed   Mentions:    Fields:    
    26. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. Lung Cancer. 2019 07; 133:103-109. Liang SK, Ko JC, Yang JC, Shih JY. PMID: 31200815.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. J Immunother. 2019 05; 42(4):126-135. Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, Fine HA, Rosenberg SA. PMID: 30882547.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    28. First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting. Ther Adv Med Oncol. 2019; 11:1758835919836374. Park K, Wan-Teck Lim D, Okamoto I, Yang JC. PMID: 31019567.
      View in: PubMed   Mentions:
    29. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer. 2019 06; 132:126-131. Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N. PMID: 31097085.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    30. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer. 2019 07; 133:10-19. Schuler M, Paz-Ares L, Sequist LV, Hirsh V, Lee KH, Wu YL, Lu S, Zhou C, Feng J, Ellis SH, Samuelsen CH, Tang W, Märten A, Ehrnrooth E, Park K, Yang JC. PMID: 31200814.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    31. Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment? Lancet Oncol. 2019 05; 20(5):602-603. Yang JC. PMID: 30975629.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unit. J Formos Med Assoc. 2019 Jun; 118(6):995-1004. Hsiue EH, Lee PL, Chen YH, Wu TH, Cheng CF, Cheng KM, Yang PC, Chen HW, Lin PY, Chiang DL, Wu HD, Yang JC, Yu CJ. PMID: 30857753.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    33. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. J Cancer Res Clin Oncol. 2019 Jun; 145(6):1569-1579. Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K. PMID: 30783814.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    34. Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. J Thorac Oncol. 2019 05; 14(5):933-939. Yang JC, Shepherd FA, Kim DW, Lee GW, Lee JS, Chang GC, Lee SS, Wei YF, Lee YG, Laus G, Collins B, Pisetzky F, Horn L. PMID: 30763730.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    35. Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors. Target Oncol. 2019 02; 14(1):57-65. Doi T, Yang JC, Shitara K, Naito Y, Cheng AL, Sarashina A, Pronk LC, Takeuchi Y, Lin CC. PMID: 30725402.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    36. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Int J Cancer. 2019 06 01; 144(11):2887-2896. Lin YT, Chen JS, Liao WY, Ho CC, Hsu CL, Yang CY, Chen KY, Lee JH, Lin ZZ, Shih JY, Yang JC, Yu CJ. PMID: 30485437.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    37. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J Thorac Oncol. 2019 03; 14(3):553-559. Yang JC, Gadgeel SM, Sequist LV, Wu CL, Papadimitrakopoulou VA, Su WC, Fiore J, Saraf S, Raftopoulos H, Patnaik A. PMID: 30529597.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    38. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2019 03 15; 125(6):892-901. Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G. PMID: 30512189.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    39. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Future Oncol. 2018 Nov; 14(27):2861-2874. Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Golembesky A, Märten A, Cufer T. PMID: 30336693.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    40. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018 11 22; 379(21):2027-2039. Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. PMID: 30280657.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    41. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 11 01; 36(31):3101-3109. Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, Chia V, Glaser S, Pultar P, Zhao S, Peng B, Akimov M, Tan DSW. PMID: 30156984.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    42. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer. 2018 11; 125:273-281. Gadgeel SM, Stevenson JP, Langer CJ, Gandhi L, Borghaei H, Patnaik A, Villaruz LC, Gubens M, Hauke R, Yang JC, Sequist LV, Bachman R, Saraf S, Raftopoulos H, Papadimitrakopoulou V. PMID: 30429032.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    43. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 01; 14(1):124-129. Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller SM, Gandhi L. PMID: 30138764.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    44. Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. Genes Chromosomes Cancer. 2018 10; 57(10):513-521. Wu SG, Liu YN, Yu CJ, Yang JC, Shih JY. PMID: 30107055.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations. Cancer Sci. 2018 Sep; 109(9):2852-2862. Murakami H, Nokihara H, Hayashi H, Seto T, Park K, Azuma K, Tsai CM, Yang JC, Nishio M, Kim SW, Kiura K, Inoue A, Takeda K, Kang JH, Nakagawa T, Takeda K, Akazawa R, Kaneko Y, Shimazaki M, Morita S, Fukuoka M, Nakagawa K. PMID: 29972716.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    46. Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. J Thorac Oncol. 2018 12; 13(12):1897-1905. Peters S, Curioni-Fontecedro A, Nechushtan H, Shih JY, Liao WY, Gautschi O, Spataro V, Unk M, Yang JC, Lorence RM, Carrière P, Cseh A, Chang GC. PMID: 30096481.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    47. Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis-Reply. JAMA Oncol. 2018 08 01; 4(8):1138-1139. Gebski V, Yang JC, Lee CK. PMID: 29931217.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    48. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases. J Immunother. 2018 Jun; 41(5):241-247. Mehta GU, Malekzadeh P, Shelton T, White DE, Butman JA, Yang JC, Kammula US, Goff SL, Rosenberg SA, Sherry RM. PMID: 29672342.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    49. Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials? Expert Opin Pharmacother. 2018 06; 19(8):851-864. Liao BC, Lin CC, Yang JC. PMID: 29726292.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    50. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study. J Formos Med Assoc. 2019 Jan; 118(1 Pt 2):230-236. Wu TH, Lee LJ, Yuan CT, Chen TW, Yang JC. PMID: 29709339.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    51. Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. J Cancer. 2018; 9(10):1813-1820. Lin SY, Yang CY, Liao BC, Ho CC, Liao WY, Chen KY, Tsai TH, Hsu CL, Hsu WH, Su KY, Chang YL, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. PMID: 29805708.
      View in: PubMed   Mentions:
    52. Real-World or Controlled Clinical Trial Data in Real-World Practice. J Thorac Oncol. 2018 04; 13(4):470-472. Wu TH, Yang JC. PMID: 29576285.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    53. Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. Clin Drug Investig. 2018 Apr; 38(4):319-331. Mann H, Andersohn F, Bodnar C, Mitsudomi T, Mok TSK, Yang JC, Hoyle C. PMID: 29247383.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    54. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 05 10; 36(14):1405-1411. Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, Yang JJ, Yamamoto N, Ahn MJ, Takahashi T, Yamanaka T, Kemner A, Roychowdhury D, Paolini J, Usari T, Wilner KD, Goto K. PMID: 29596029.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    55. The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. J Thorac Oncol. 2018 06; 13(6):792-800. Lee CK, Lord S, Marschner I, Wu YL, Sequist L, Rosell R, Fukuoka M, Mitsudomi T, Asher R, Davies L, Gebski V, Gralla R, Mok T, Yang JC. PMID: 29580950.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    56. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). Patient. 2018 02; 11(1):131-141. Wu YL, Hirsh V, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N, O'Byrne K, Geater SL, Zhou C, Massey D, Märten A, Lungershausen J, Yang JC. PMID: 29178024.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    57. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Feb 01; 4(2):210-216. Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T, Yang JC. PMID: 29270615.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    58. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients. Clin Lung Cancer. 2018 05; 19(3):e361-e372. Wu TH, Hsiue EH, Lee JH, Lin CC, Liao WY, Ho CC, Shih JY, Yu CJ, Yang JC. PMID: 29477365.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    59. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. Lancet Respir Med. 2018 02; 6(2):107-116. Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY, Lee JH, Tsai TH, Su KY, Hsieh MS, Chang YL, Bai YY, Huang DD, Thress KS, Yang JC. PMID: 29249325.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    60. Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. Br J Cancer. 2018 01; 118(1):38-42. Gadgeel S, Shaw AT, Barlesi F, Crinò L, Yang JC, Dingemans AC, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Kotb A, Ou SI. PMID: 29149104.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    61. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ß-blockers. Sci Transl Med. 2017 Nov 08; 9(415). Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. PMID: 29118262.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    62. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. Radiother Oncol. 2018 Feb; 126(2):368-374. Yang WC, Xiao F, Shih JY, Ho CC, Chen YF, Tseng HM, Chen KY, Liao WY, Yu CJ, Yang JC, Kuo SH, Cheng JC, Yang PC, Hsu FM. PMID: 29111173.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    63. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017 11; 5(11):891-902. Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, Kim HR, John T, Kao S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang Z, Yang JC. PMID: 29056570.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    64. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. J Clin Oncol. 2017 Dec 20; 35(36):4027-4034. Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC. PMID: 28968167.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    65. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2017 Nov 10; 35(32):3662-3670. Kubota K, Yoshioka H, Oshita F, Hida T, Yoh K, Hayashi H, Kato T, Kaneda H, Yamada K, Tanaka H, Ichinose Y, Park K, Cho EK, Lee KH, Lin CB, Yang JC, Hara K, Asato T, Nakagawa K. PMID: 28902534.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    66. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 03 20; 36(9):841-849. Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenkov Y, Ghiorghiu S, Stetson D, Markovets A, Barrett JC, Thress KS, Jänne PA. PMID: 28841389.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    67. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. J Clin Oncol. 2017 Oct 10; 35(29):3322-3329. Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA. PMID: 28809608.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    68. Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. J Thorac Oncol. 2017 10; 12(10):1588-1594. Thress KS, Jacobs V, Angell HK, Yang JC, Sequist LV, Blackhall F, Su WC, Schuler M, Wolf J, Gold KA, Cantarini M, Barrett JC, Jänne PA. PMID: 28751247.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    69. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. Eur J Cancer. 2017 09; 82:27-33. Gandhi L, Ou SI, Shaw AT, Barlesi F, Dingemans AC, Kim DW, Camidge DR, Hughes BGM, Yang JC, de Castro J, Crino L, Léna H, Do P, Golding S, Bordogna W, Zeaiter A, Kotb A, Gadgeel S. PMID: 28646771.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    70. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 10; 12(10):1552-1560. Yang JC, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B, Morcos PN, Zeaiter A, Shaw AT. PMID: 28689043.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    71. A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018 01; 19(1):27-34. Yang JC, Mok T, Han B, Orlando M, Puri T, Park K. PMID: 28743421.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    72. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1040-1048. Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Sulman E, McCutcheon IE, Azeem S, Cahill D, Tatsui C, Heimberger AB, Ferguson S, Ghia A, Demonte F, Raza S, Guha-Thakurta N, Yang J, Sawaya R, Hess KR, Rao G. PMID: 28687375.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    73. A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. Oncotarget. 2017 Jun 20; 8(25):41474-41486. Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, Lee JH, Yang JC, Zhao M, Zhou C, Lee JK, Lee SH, Lee JY, Ahn MJ, Tan TJ, Tan DS, Tan EH, Ong ST, Lim WT. PMID: 28467813.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    74. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 08; 12(8):1183-1209. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. PMID: 28579481.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    75. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. J Natl Cancer Inst. 2017 06 01; 109(6). Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, Yang JC. PMID: 28376144.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    76. EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. J Thorac Oncol. 2017 08; 12(8):1247-1256. Jenkins S, Yang JC, Jänne PA, Thress KS, Yu K, Hodge R, Weston S, Dearden S, Patel S, Cantarini M, Shepherd FA. PMID: 28527899.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    77. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. Lung Cancer. 2017 08; 110:7-13. Liao BC, Lin CC, Lee JH, Yang JC. PMID: 28676222.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    78. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 07; 12(7):1061-1070. Jenkins S, Yang JC, Ramalingam SS, Yu K, Patel S, Weston S, Hodge R, Cantarini M, Jänne PA, Mitsudomi T, Goss GD. PMID: 28428148.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    79. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. J Clin Oncol. 2017 Jun 01; 35(16):1803-1813. Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, Klebanoff CA, Kammula US, Sherman M, Perez A, Yuan CM, Feldman T, Friedberg JW, Roschewski MJ, Feldman SA, McIntyre L, Toomey MA, Rosenberg SA. PMID: 28291388.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCells
    80. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017 May 01; 35(13):1403-1410. Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. PMID: 28447912.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    81. Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. Am J Respir Crit Care Med. 2017 03 01; 195(5):663-673. Chang IS, Jiang SS, Yang JC, Su WC, Chien LH, Hsiao CF, Lee JH, Chen CY, Chen CH, Chang GC, Wang Z, Lo FY, Chen KY, Wang WC, Chen YM, Huang MS, Tsai YH, Su YC, Hsieh WS, Shih WC, Shieh SH, Yang TY, Lan Q, Rothman N, Chen CJ, Chanock SJ, Yang PC, Hsiung CA. PMID: 27669169.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    82. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017 Apr 20; 35(12):1288-1296. Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA. PMID: 28221867.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCTClinical Trials
    83. Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. Curr Oncol Rep. 2017 Jan; 19(1):4. Liao BC, Lin CC, Yang JC. PMID: 28138934.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    84. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 05; 18(3):324-332.e1. Lin YT, Liu YN, Wu SG, Yang JC, Shih JY. PMID: 28089594.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    85. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. Br J Cancer. 2017 Jan 17; 116(2):175-185. Wu YL, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Schuler M, Mok T, Yamamoto N, O'Byrne K, Hirsh V, Gibson N, Massey D, Kim M, Yang JC. PMID: 28006816.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    86. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 04; 12(4):633-643. Ding PN, Lord SJ, Gebski V, Links M, Bray V, Gralla RJ, Yang JC, Lee CK. PMID: 28007626.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    87. New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. Expert Rev Respir Med. 2017 01; 11(1):51-55. Wu TH, Hsiue EH, Lee JH, Lin CC, Yang JC. PMID: 27927060.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    88. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. Sci Transl Med. 2016 12 07; 8(368):368ra172. Yang Z, Guo Q, Wang Y, Chen K, Zhang L, Cheng Z, Xu Y, Yin X, Bai Y, Rabbie S, Kim DW, Ahn MJ, Yang JC, Zhang X. PMID: 27928026.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    89. Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al. J Clin Oncol. 2017 02 20; 35(6):694-695. Yang JC, Puri T, Orlando M, Cheng Y. PMID: 27918723.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    90. Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib. J Thorac Oncol. 2017 03; 12(3):567-572. Ho CC, Liao WY, Lin CA, Shih JY, Yu CJ, Yang JC. PMID: 27923714.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    91. Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. J Biomed Sci. 2016 Dec 03; 23(1):86. Liao BC, Lin CC, Lee JH, Yang JC. PMID: 27912760.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    92. Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. Cold Spring Harb Mol Case Stud. 2016 11; 2(6):a001263. Biswas R, Gao S, Cultraro CM, Maity TK, Venugopalan A, Abdullaev Z, Shaytan AK, Carter CA, Thomas A, Rajan A, Song Y, Pitts S, Chen K, Bass S, Boland J, Hanada KI, Chen J, Meltzer PS, Panchenko AR, Yang JC, Pack S, Giaccone G, Schrump DS, Khan J, Guha U. PMID: 27900369.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    93. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 12; 34(34):4079-4085. Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, Camidge DR, De Petris L, Kim DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A, Yang JC, Han JY, Bordogna W, Golding S, Zeaiter A, Ou SI. PMID: 27863201.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    94. Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer. Expert Rev Mol Diagn. 2016 12; 16(12):1251-1257. Hsiue EH, Lee JH, Lin CC, Yang JC. PMID: 27737606.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    95. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. J Thorac Oncol. 2017 02; 12(2):403-407. Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, Yang JC. PMID: 27765535.
      View in: PubMed   Mentions: 94     Fields:    Translation:Humans
    96. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov; 17(11):1497-1508. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L. PMID: 27745820.
      View in: PubMed   Mentions: 220     Fields:    Translation:HumansCTClinical Trials
    97. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol. 2017 02; 12(2):194-207. Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Yang JC, Zhou C, Vokes E. PMID: 27729297.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    98. Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer. Case Rep Oncol. 2016 May-Aug; 9(2):474-480. Lu SL, Hsu FM, Chen KY, Ho CC, Yang JC, Cheng JC. PMID: 27721771.
      View in: PubMed   Mentions:
    99. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. J Clin Oncol. 2016 09 20; 34(27):3258-66. Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. PMID: 27507876.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    100. A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. J Thorac Oncol. 2016 10; 11(10):1736-44. Mok TS, Geater SL, Su WC, Tan EH, Yang JC, Chang GC, Han M, Komarnitsky P, Payumo F, Garrus JE, Close S, Park K. PMID: 27448761.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    101. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res. 2016 Oct 15; 22(20):5130-5140. Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, Box M, Johnström P, Varnäs K, Malmquist J, Thress KS, Jänne PA, Cross D. PMID: 27435396.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansAnimalsCells
    102. Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice. J Cancer. 2016; 7(11):1515-23. Liang YH, Shao YY, Liao BC, Lee HS, Yang JC, Chen HM, Chiang CJ, Cheng AL, Lai MS. PMID: 27471567.
      View in: PubMed   Mentions:
    103. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 10 01; 34(28):3375-82. Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JC, Barrett JC, Jänne PA. PMID: 27354477.
      View in: PubMed   Mentions: 124     Fields:    Translation:HumansCTClinical Trials
    104. Safety of gefitinib in non-small cell lung cancer treatment. Expert Opin Drug Saf. 2016 Jul; 15(7):993-1000. Hsiue EH, Lee JH, Lin CC, Yang JC. PMID: 27212579.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    105. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. J Clin Oncol. 2016 07 10; 34(20):2389-97. Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, Lu L, Kwong ML, Ilyas S, Klemen ND, Payabyab EC, Morton KE, Toomey MA, Steinberg SM, White DE, Rosenberg SA. PMID: 27217459.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCells
    106. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. J Thorac Oncol. 2016 07; 11(7):1140-52. Chen YF, Hsieh MS, Wu SG, Chang YL, Yu CJ, Yang JC, Yang PC, Shih JY. PMID: 27094798.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    107. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 05; 17(5):577-89. Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. PMID: 27083334.
      View in: PubMed   Mentions: 138     Fields:    Translation:HumansCTClinical Trials
    108. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. Clin Lung Cancer. 2016 09; 17(5):e77-e94. Lin YT, Yu CJ, Yang JC, Shih JY. PMID: 27130468.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    109. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget. 2016 Mar 15; 7(11):12404-13. Wu SG, Liu YN, Tsai MF, Chang YL, Yu CJ, Yang PC, Yang JC, Wen YF, Shih JY. PMID: 26862733.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    110. Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer. 2016 Apr; 94:46-53. Chen LY, Molina-Vila MA, Ruan SY, Su KY, Liao WY, Yu KL, Ho CC, Shih JY, Yu CJ, Yang JC, Rosell R, Yang PC. PMID: 26973206.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    111. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. J Thorac Oncol. 2016 Mar; 11(3):380-90. Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. PMID: 26823294.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    112. The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. PLoS One. 2015; 10(12):e0145936. Chiang Y, Yang JC, Hsu FM, Chen YH, Shih JY, Lin ZZ, Lan KH, Cheng AL, Kuo SH. PMID: 26720170.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    113. First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. J Thorac Oncol. 2016 Mar; 11(3):370-9. Yang JC, Srimuninnimit V, Ahn MJ, Lin CC, Kim SW, Tsai CM, Mok T, Orlando M, Puri T, Wang X, Park K. PMID: 26725183.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    114. First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial. Clin Lung Cancer. 2016 Mar; 17(2):150-60. Boye M, Wang X, Srimuninnimit V, Kang JH, Tsai CM, Orlando M, Puri T, Kim JS, Rajan N, Yang JC. PMID: 26809984.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    115. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. J Thorac Oncol. 2015 Dec; 10(12):1745-53. Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, Seto T, Wu YL, Novello S, Juhász E, Arén O, Sun Y, Schmelter T, Ong TJ, Peña C, Smit EF, Mok TS. PMID: 26743856.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    116. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. J Thorac Oncol. 2015 Dec; 10(12):1754-61. Liao BC, Lee JH, Lin CC, Chen YF, Chang CH, Ho CC, Shih JY, Yu CJ, Yang JC. PMID: 26334749.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    117. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol. 2016 Mar 01; 34(7):661-8. Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW. PMID: 26598747.
      View in: PubMed   Mentions: 145     Fields:    Translation:HumansCTClinical Trials
    118. Toxicities Associated With Adoptive T-Cell Transfer for Cancer. Cancer J. 2015 Nov-Dec; 21(6):506-9. Yang JC. PMID: 26588684.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    119. Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol. 2015 Sep; 7(5):274-90. Liao BC, Lin CC, Shih JY, Yang JC. PMID: 26327925.
      View in: PubMed   Mentions:
    120. Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene. J Thorac Oncol. 2015 Sep; 10(9):e95-e96. Wu H, Shih JY, Yang JC. PMID: 26291023.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    121. The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia. Oncologist. 2015 Sep; 20(9):1051-7. Kuo HY, Lin ZZ, Kuo R, Shau WY, Lai CL, Yang YY, Shao YY, Hsu C, Cheng WF, Cheng AL, Yang JC, Lai MS. PMID: 26240133.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    122. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015 Aug; 16(8):990-8. Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS. PMID: 26159065.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCTClinical Trials
    123. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul; 16(7):830-8. Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. PMID: 26051236.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansCTClinical Trials
    124. IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. Oncotarget. 2015 Apr 30; 6(12):10415-31. Liu YN, Chang TH, Tsai MF, Wu SG, Tsai TH, Chen HY, Yu SL, Yang JC, Shih JY. PMID: 25871388.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    125. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015 Apr 30; 372(18):1689-99. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. PMID: 25923549.
      View in: PubMed   Mentions: 412     Fields:    Translation:HumansCTClinical Trials
    126. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015 Jun 20; 33(18):2092-9. Weber JS, Yang JC, Atkins MB, Disis ML. PMID: 25918278.
      View in: PubMed   Mentions: 98     Fields:    Translation:HumansCells
    127. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. J Clin Oncol. 2015 Jun 10; 33(17):1958-65. Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, Gebski V, Gralla RJ, Yang JC. PMID: 25897154.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    128. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015 May 10; 33(14):1543-50. Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS. PMID: 25823737.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCells
    129. Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells. PLoS One. 2015; 10(3):e0119135. Tang MC, Wu MY, Hwang MH, Chang YT, Huang HJ, Lin AM, Yang JC. PMID: 25807554.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    130. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. Lung Cancer. 2015 May; 88(2):208-14. Tsai TH, Wu SG, Hsieh MS, Yu CJ, Yang JC, Shih JY. PMID: 25773866.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    131. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015 Mar; 27(2):94-101. Liao BC, Lin CC, Yang JC. PMID: 25611025.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    132. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb; 16(2):141-51. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. PMID: 25589191.
      View in: PubMed   Mentions: 316     Fields:    Translation:HumansCTClinical Trials
    133. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol. 2014 Nov; 9(11):1720-5. Lin YT, Wang YF, Yang JC, Yu CJ, Wu SG, Shih JY, Yang PC. PMID: 25436806.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    134. Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma. Clin Lung Cancer. 2015 Mar; 16(2):137-43. Liao BC, Shao YY, Chen HM, Shau WY, Lin ZZ, Kuo RN, Lai CL, Chen KH, Cheng AL, Yang JC, Lai MS. PMID: 25450871.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    135. Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosis. J Geriatr Oncol. 2015 Jan; 6(1):38-45. Hsu CL, Chen JH, Chen KY, Shih JY, Yang JC, Yu CJ, Yang PC. PMID: 25245172.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    136. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer. J Thorac Oncol. 2014 Sep; 9(9):1385-92. Lee JH, Lin YL, Hsu WH, Chen HY, Chang YC, Yu CJ, Shih JY, Lin CC, Chen KY, Ho CC, Laio WY, Yang PC, Yang JC. PMID: 25057939.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    137. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS). J Thorac Oncol. 2014 Sep; 9(9):1411-7. Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Marsland T, Patel T, Rubin M, White L, Yang JC, Klughammer B, Colburn D, Miller V, Johnson BE. PMID: 25122437.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    138. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015 Feb 20; 33(6):540-9. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA. PMID: 25154820.
      View in: PubMed   Mentions: 386     Fields:    Translation:HumansCellsCTClinical Trials
    139. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. J Thorac Oncol. 2014 Aug; 9(8):1171-9. Chen YF, Hsieh MS, Wu SG, Chang YL, Shih JY, Liu YN, Tsai MF, Tsai TH, Yu CJ, Yang JC, Yang PC. PMID: 25157770.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    140. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. Eur J Cancer. 2014 Sep; 50(13):2219-30. Yang JC, Kang JH, Mok T, Ahn MJ, Srimuninnimit V, Lin CC, Kim DW, Tsai CM, Barraclough H, Altug S, Orlando M, Park K. PMID: 24953333.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    141. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis. Lung Cancer. 2014 Aug; 85(2):230-8. Popat S, Mok T, Yang JC, Wu YL, Lungershausen J, Stammberger U, Griebsch I, Fonseca T, Paz-Ares L. PMID: 24929780.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    142. Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial. Ann Surg Oncol. 2014 Aug; 21(8):2484-9. Beane JD, Yang JC, White D, Steinberg SM, Rosenberg SA, Rudloff U. PMID: 24756814.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    143. Reply to E.R. Haspinger et al. J Clin Oncol. 2014 Mar 10; 32(8):863-4. Yang JC, Sequist LV. PMID: 24493734.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    144. Reply to F. De Marinis et al. J Clin Oncol. 2014 Mar 10; 32(8):865. Yang JC, Sequist LV. PMID: 24493733.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    145. Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer. 2014 May 01; 120(9):1426-32. Tseng J, Citrin DE, Waldman M, White DE, Rosenberg SA, Yang JC. PMID: 24474396.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsPHPublic Health
    146. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2014 May; 15(3):173-81. Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F. PMID: 24486058.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    147. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer. 2014 Feb; 83(2):174-81. Yang JC, Wu YL, Chan V, Kurnianda J, Nakagawa K, Saijo N, Fukuoka M, McWalter G, McCormack R, Mok TS. PMID: 24361280.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    148. Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. PLoS One. 2013; 8(11):e80276. Lin ZZ, Shau WY, Hsu C, Shao YY, Yeh YC, Kuo RN, Hsu CH, Yang JC, Cheng AL, Lai MS. PMID: 24244668.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    149. Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. Lung Cancer. 2013 Dec; 82(3):420-5. Tsai TH, Yang CY, Ho CC, Liao WY, Jan IS, Chen KY, Wang JY, Ruan SY, Yu CJ, Yang JC, Yang PC, Shih JY. PMID: 24183104.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsPHPublic Health
    150. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2013 Nov 01; 31(31):3926-34. Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, Bowden C, Miller V. PMID: 24101054.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    151. Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas. J Neurooncol. 2013 Oct; 115(1):61-70. Wu PF, Huang WC, Yang JC, Lu YS, Shih JY, Wu SG, Lin CH, Cheng AL. PMID: 23817810.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    152. EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. Future Oncol. 2013 Jul; 9(7):991-1003. Kao HF, Lin CC, Yang JC. PMID: 23837762.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    153. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20; 31(27):3327-34. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. PMID: 23816960.
      View in: PubMed   Mentions: 663     Fields:    Translation:HumansCTClinical Trials
    154. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20; 31(27):3342-50. Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. PMID: 23816967.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCTClinical Trials
    155. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol. 2013 Jun 10; 31(17):2152-9. Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA. PMID: 23650429.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCellsCTClinical Trials
    156. A selective ALK inhibitor in ALK-rearranged patients. Lancet Oncol. 2013 Jun; 14(7):564-5. Yang JC. PMID: 23639469.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    157. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013 May 01; 105(9):595-605. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu da T, Zaatar A, Osorio Sanchez JA, Vu VV, Au JS, Inoue A, Lee SM, Gebski V, Yang JC. PMID: 23594426.
      View in: PubMed   Mentions: 145     Fields:    Translation:Humans
    158. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. Lung Cancer. 2013 Aug; 81(2):280-7. Wu YL, Fukuoka M, Mok TS, Saijo N, Thongprasert S, Yang JC, Chu DT, Yang JJ, Rukazenkov Y. PMID: 23540718.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    159. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013 Jun; 13(6):729-36. Yang JC, Reguart N, Barinoff J, Köhler J, Uttenreuther-Fischer M, Stammberger U, O'Brien D, Wolf J, Cohen EE. PMID: 23506556.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    160. First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments. Drugs. 2013 Mar; 73(4):357-69. Liao BC, Lin CC, Yang JC. PMID: 23479407.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    161. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol. 2013 Feb; 8(2):229-37. Hirsh V, Cadranel J, Cong XJ, Fairclough D, Finnern HW, Lorence RM, Miller VA, Palmer M, Yang JC. PMID: 23328549.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    162. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):418-24. Liao WY, Chen JH, Wu M, Shih JY, Chen KY, Ho CC, Yang JC, Yu CJ. PMID: 23291258.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    163. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol Oncol. 2013 Feb; 7(1):112-20. Huang MH, Lee JH, Chang YJ, Tsai HH, Lin YL, Lin AM, Yang JC. PMID: 23102728.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    164. Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study. Transl Lung Cancer Res. 2012 Sep; 1(3):227-9. Liao BC, Yang JC. PMID: 25806186.
      View in: PubMed   Mentions:
    165. Small-cell lung cancer treatment: where is the target? J Thorac Oncol. 2012 Sep; 7(9):1327-8. Yang JC. PMID: 22895135.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    166. ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett. 2013 Jan 01; 328(1):144-51. Huang CP, Tsai MF, Chang TH, Tang WC, Chen SY, Lai HH, Lin TY, Yang JC, Yang PC, Shih JY, Lin SB. PMID: 22935675.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    167. Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer. Eur J Cancer. 2013 Jan; 49(1):106-14. Shao YY, Shau WY, Lin ZZ, Chen HM, Kuo R, Yang JC, Lai MS. PMID: 22897841.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    168. Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: an east asian population-based study. Oncologist. 2012; 17(10):1294-302. Lin ZZ, Shau WY, Shao YY, Yang YY, Kuo RN, Yang JC, Lai MS. PMID: 22826374.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    169. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012 Jul 31; 109(31):E2127-33. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W. PMID: 22773810.
      View in: PubMed   Mentions: 166     Fields:    Translation:HumansCells
    170. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol. 2012 Jun; 7(6):973-81. Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM, Yu CJ. PMID: 22551904.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    171. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. Lung Cancer. 2012 Aug; 77(2):346-52. Ahn MJ, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M. PMID: 22534669.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    172. Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR. Clin Cancer Res. 2012 Jun 15; 18(12):3470-7. Chung KP, Wu SG, Wu JY, Yang JC, Yu CJ, Wei PF, Shih JY, Yang PC. PMID: 22510346.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    173. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012 May; 13(5):528-38. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC. PMID: 22452896.
      View in: PubMed   Mentions: 269     Fields:    Translation:HumansCTClinical Trials
    174. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May; 13(5):539-48. Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. PMID: 22452895.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansCTClinical Trials
    175. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012 Apr 01; 18(7):2039-47. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. PMID: 22271879.
      View in: PubMed   Mentions: 170     Fields:    Translation:Humans
    176. Survival of patients with small cell lung carcinoma in Taiwan. Oncology. 2012; 82(1):19-24. Kuo YH, Lin ZZ, Yang YY, Shao YY, Shau WY, Kuo RN, Yang JC, Lai MS. PMID: 22269348.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    177. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012 Feb 01; 30(4):433-40. Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, Yang PC. PMID: 22215752.
      View in: PubMed   Mentions: 144     Fields:    Translation:Humans
    178. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol. 2011 Nov; 6(11):1872-80. Thongprasert S, Duffield E, Saijo N, Wu YL, Yang JC, Chu DT, Liao M, Chen YM, Kuo HP, Negoro S, Lam KC, Armour A, Magill P, Fukuoka M. PMID: 22011650.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    179. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. Clin Cancer Res. 2011 Oct 15; 17(20):6459-66. Medema RH, Lin CC, Yang JC. PMID: 22003073.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    180. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer. 2011 Oct 07; 11:430. Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, Ely G, Yang JC, Mok T. PMID: 21982342.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    181. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. J Thorac Oncol. 2011 Oct; 6(10):1663-9. Salto-Tellez M, Tsao MS, Shih JY, Thongprasert S, Lu S, Chang GC, Au JS, Chou TY, Lee JS, Shi YK, Radzi A, Kang JH, Kim SW, Tan SY, Yang JC. PMID: 21869714.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    182. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25. Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA. PMID: 21597387.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    183. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011 Jul 20; 29(21):2866-74. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. PMID: 21670455.
      View in: PubMed   Mentions: 415     Fields:    Translation:HumansCTClinical Trials
    184. Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy. J Immunother. 2011 May; 34(4):397-402. Langan RC, Prieto PA, Sherry RM, Zlott D, Wunderlich J, Csako G, Costello R, White DE, Rosenberg SA, Yang JC. PMID: 21499128.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    185. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011 Jul 01; 17(13):4550-7. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. PMID: 21498393.
      View in: PubMed   Mentions: 579     Fields:    Translation:HumansCellsCTClinical Trials
    186. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011 Mar 01; 29(7):917-24. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA. PMID: 21282551.
      View in: PubMed   Mentions: 491     Fields:    Translation:HumansCellsCTClinical Trials
    187. Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations. Drugs. 2011 Jan 01; 71(1):79-88. Lin CC, Yang JC. PMID: 21175241.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    188. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother. 2010 Oct; 33(8):840-7. Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM, White D, Rosenberg SA, Dudley ME, Yang JC. PMID: 20842052.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    189. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010 Oct; 33(8):828-33. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA. PMID: 20842054.
      View in: PubMed   Mentions: 252     Fields:    Translation:HumansCTClinical Trials
    190. Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Ann Surg Oncol. 2010 Jan; 17(1):163-70. Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA, Avital I. PMID: 19777192.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    191. Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist. 2008 Oct; 13(10):1055-62. Stein WD, Yang J, Bates SE, Fojo T. PMID: 18827177.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    192. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008 Nov 10; 26(32):5233-9. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA. PMID: 18809613.
      View in: PubMed   Mentions: 484     Fields:    Translation:HumansCellsCTClinical Trials
    193. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008 Jul 15; 113(2):293-301. Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S. PMID: 18457330.
      View in: PubMed   Mentions: 101     Fields:    Translation:Humans
    194. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007 Nov-Dec; 30(8):825-30. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA. PMID: 18049334.
      View in: PubMed   Mentions: 194     Fields:    Translation:HumansCTClinical Trials
    195. Immunotherapy for renal cell cancer. J Clin Oncol. 2006 Dec 10; 24(35):5576-83. Yang JC, Childs R. PMID: 17158543.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    196. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006 May 20; 24(15):2283-9. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. PMID: 16710025.
      View in: PubMed   Mentions: 185     Fields:    Translation:Humans
    197. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005 Sep 01; 23(25):6043-53. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA. PMID: 16087944.
      View in: PubMed   Mentions: 244     Fields:    Translation:HumansCTClinical Trials
    198. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005 Apr 01; 23(10):2346-57. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. PMID: 15800326.
      View in: PubMed   Mentions: 506     Fields:    Translation:HumansCellsCTClinical Trials
    199. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004 Sep; 10(9):909-15. Rosenberg SA, Yang JC, Restifo NP. PMID: 15340416.
      View in: PubMed   Mentions: 776     Fields:    Translation:HumansCells
    200. A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J Immunother. 2004 Jul-Aug; 27(4):259-64. Elaraj DM, White DE, Steinberg SM, Haworth L, Rosenberg SA, Yang JC. PMID: 15235386.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    201. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother. 2003 Sep-Oct; 26(5):385-93. Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME. PMID: 12973027.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    202. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003 Aug 15; 21(16):3127-32. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA. PMID: 12915604.
      View in: PubMed   Mentions: 161     Fields:    Translation:HumansCTClinical Trials
    203. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003 Jul 31; 349(5):427-34. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. PMID: 12890841.
      View in: PubMed   Mentions: 612     Fields:    Translation:HumansCTClinical Trials
    204. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer. 2002 Oct 15; 95(8):1637-43. Feldman AL, Alexander HR, Yang JC, Linehan WM, Eyler RA, Miller MS, Steinberg SM, Libutti SK. PMID: 12365010.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    205. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):142-52. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA. PMID: 11773163.
      View in: PubMed   Mentions: 145     Fields:    Translation:HumansCellsCTClinical Trials
    James's Networks
    Concepts (445)
    Derived automatically from this person's publications.
    _
    Co-Authors (9)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _